Irosustat

Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibit

Retrieved on: 
Tuesday, January 19, 2021

In the Nature Medicine publication, Dr. Hickey and colleagues provide scientific evidence supporting a new discovery in breast cancer demonstrating that the androgen receptor acts like a tumor suppressor.

Key Points: 
  • In the Nature Medicine publication, Dr. Hickey and colleagues provide scientific evidence supporting a new discovery in breast cancer demonstrating that the androgen receptor acts like a tumor suppressor.
  • Further, enobosarm, by activating the androgen receptor, has demonstrated antitumor activity in both estrogen receptor targeted endocrine therapy resistant and CDK4/6 inhibitor resistant metastatic human breast cancer models.
  • This study clears up the confusion in the scientific field regarding the role that the androgen receptor is playing in ER+ breast cancer.
  • The Veru breast cancer pipeline includes enobosarm for hormone sensitive metastatic ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer.

Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer

Retrieved on: 
Wednesday, December 9, 2020

Two Phase 2 clinical studies were conducted in approximately 150 heavily pretreated patients with ER+ HER2- metastatic breast cancer who developed resistance to current estrogen endocrine therapy, with positive efficacy and safety clinical results.

Key Points: 
  • Two Phase 2 clinical studies were conducted in approximately 150 heavily pretreated patients with ER+ HER2- metastatic breast cancer who developed resistance to current estrogen endocrine therapy, with positive efficacy and safety clinical results.
  • By targeting the AR in ER+ HER2- metastatic breast cancer, enobosarm introduces a novel endocrine therapy to patients with breast cancer that have exhausted endocrine therapies targeting ER, but prior to IV chemotherapy.
  • VERU-111 is being evaluated in open label Phase 1b and Phase 2 clinical studies in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer.
  • The Veru breast cancer pipeline includes enobosarm for hormone sensitive metastatic ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer.

GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer

Retrieved on: 
Friday, April 24, 2020

GARNET is the largest dataset evaluating an anti-PD-1 in endometrial cancer.

Key Points: 
  • GARNET is the largest dataset evaluating an anti-PD-1 in endometrial cancer.
  • We believe in the clinical potential of dostarlimab for women with advanced or recurrent dMMR endometrial cancer who urgently need additional treatment options for this incurable disease.
  • The safety population included all patients with dMMR endometrial cancer who received at least one dose of dostarlimab (n=104).
  • Endometrial cancer is the sixth most common cancer in women worldwide.vi
    GSK is focused on maximizing patient survival through transformational medicines.